Featuring: publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX & OTC: BB) and Canadian (TSX & TSX-V) stock exchanges, Investment & Money Management Ideas.

Press Release - BioSnate Pharmaceuticals, Inc. (BPAX-NASDAQ)

BioSante is a product development company. From the beginning, we have had our eye on women’s sexual health. Right now, we are developing a product, LibiGel®, for the treatment of female sexual dysfunction for which there is no product approved in the United States. We believe this represents a blockbuster opportunity. - Stephen M. Simes (BPAX) (Interview published March 11, 2011)

The Most Powerful Name In Corporate News and Information.


Members Login

Become A Member!


BioSante Pharmaceuticals, Inc. To Present

at BioCentury and BIO Healthcare Conferences

LINCOLNSHIRE, Illinois (October 17, 2011) - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that Stephen M. Simes, BioSante's president & CEO will present at two healthcare conferences in October. Mr. Simes will speak at the BioCentury NewsMakers in the Biotech Industry on Friday, October 21 at 11:30 am EDT in New York and at the BIO Investor Forum on Tuesday, October 25 at 3:30 pm PDT in San Francisco.

BioSante will provide a company overview at each conference, as well as an update on the LibiGel® (testosterone gel) Phase III clinical development program and planned new drug application (NDA) submission.

A live audio webcast of remarks by Mr. Simes, at the BioCentury conference may be accessed at http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=BPAX&item_id=4209619. A live audio webcast of remarks by Mr. Simes, at BIO Investor Forum may be accessed at http://www.veracast.com/webcasts/bio/investorforum2011/16113461.cfm. Both webcasts will be archived for 90 days.

About BioSante Pharmaceuticals, Inc.

BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD), which is in Phase III clinical development according to a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA). BioSante's first FDA-approved product is Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other BioSante products are Bio-T-Gel™, a testosterone gel for male hypogonadism, for which an NDA is pending, licensed to Teva Pharmaceuticals, and an oral contraceptive in Phase II clinical development. Additional information is available online at:


For more information, please contact:

For Media:

Harris D. McKinney, Inc.

Alan Zachary

email: azachary@mckinneychicago.com

phone: (312) 506-5220

For Investors:

The Trout Group LLC

Tricia Swanson

E-Mail: tswanson@troutgroup.com

Phone: (646) 378-2953


ceocfointerviews.com does not purchase or make
recommendation on stocks based on the interviews published.